Results 1 to 10 of about 3,514 (173)
Benefits of Sevelamer on Markers of Bone Turnover in Taiwanese Hemodialysis Patients
Journal of the Formosan Medical Association, 2010 Sevelamer hydrochloride is a recently developed phosphate binder, which is a quaternary amine anion exchanger without calcium or aluminum. Sevelamer is effective in controlling hyperphosphatemia without increasing the calcium load in chronic hemodialysis
Yu-Feng Lin +13 more
doaj +3 more sources
Sevelamer Carbonate Crystal-Induced Colitis
Case Reports in Gastrointestinal Medicine, 2020 Hyperphosphatemia is a common and well-described complication of end-stage renal disease. Despite strict dietary constraints and compliance, phosphate binders such as calcium acetate and/or sevelamer carbonate are also needed to treat secondary ...
T. Lai +3 more
doaj +2 more sources
Sevelamer-associated ischemic colitis with perforation
Gastroenterology Insights, 2015 We present a case of an 83-year-old woman with end-stage renal disease and hyperphosphatemia treated with sevelamer carbonate, who underwent subtotal colectomy for diffuse bowel necrosis and two perforations in the transverse colon.
Rachel Hudacko, Peter Kaye
doaj +2 more sources
Association between sevelamer use and outcomes in acute kidney injury with hyperphosphataemia: evidence from the MIMIC-IV [PDF]
Frontiers in PharmacologyBackgroundHyperphosphataemia is consistently linked to adverse clinical outcomes in Acute Kidney Injury (AKI). Sevelamer, a non-calcium phosphate binder widely used in chronic kidney disease (CKD), has not been adequately evaluated for efficacy in AKI ...
Shuzhen Suo +8 more
doaj +2 more sources
Phosphate Binding with Sevelamer Preserves Mechanical Competence of Bone Despite Acidosis in Advanced Experimental Renal Insufficiency. [PDF]
PLoS ONE, 2016 INTRODUCTION:Phosphate binding with sevelamer can ameliorate detrimental histomorphometric changes of bone in chronic renal insufficiency (CRI). Here we explored the effects of sevelamer-HCl treatment on bone strength and structure in experimental CRI ...
Jarkko Jokihaara +8 more
doaj +3 more sources
Emerging Effects of Sevelamer in Chronic Kidney Disease
Kidney & Blood Pressure Research, 2013 Sevelamer, a non-absorbable anion exchange resin, is used to control hyperphosphatemia in chronic kidney disease (CKD) by binding to dietary phosphate in the gastrointestinal tract.
Ryota Ikee +4 more
doaj +2 more sources
Microorganisms, 2020 Despite the use of various pharmacotherapeutic strategies, fibrosis due to nonalcoholic steatohepatitis (NASH) remains an unsatisfied clinical issue. We investigated the effect of sevelamer, a hydrophilic bile acid sequestrant, on hepatic fibrosis in a ...
Kosuke Kaji +2 more
exaly +3 more sources
Therapeutics and Clinical Risk Management, 2008 Vincenzo Savica1,2, Domenico Santoro1, Paolo Monardo2, Agostino Mallamace1, Guido Bellinghieri11Experimental and Clinic Department of Internal Medicine and Pharmacology, University of Messina, Italy; 2Nephrology and Dialysis Unit, Papardo Hospital ...
Vincenzo Savica +4 more
doaj +1 more source
Effect of Sevelamer on Calciprotein Particles in Hemodialysis Patients: The Sevelamer Versus Calcium to Reduce Fetuin-A-Containing Calciprotein Particles in Dialysis (SCaRF) Randomized Controlled Trial [PDF]
Kidney International Reports, 2020 Introduction: Calciprotein particles (CPPs) are potentially modifiable mediators of phosphate toxicity in patients with kidney disease. We compared the effects of calcium carbonate (CC) and the non–calcium-based phosphate binder sevelamer on CPP levels ...
Edward R. Smith +4 more
doaj +2 more sources
Drug Delivery, 2022 Arsenic trioxide (As2O3, ATO) has limited therapeutic benefit to treat solid tumors, whether used alone or in combination. Nanoscale drug delivery vehicles have great potential to overcome the limitation of the utility of ATO by rapid renal clearance and
Qiu-Chen Bi +10 more
doaj +2 more sources